rs121918388 — APOB APOB Q2279X

Nonsense variant creating a premature stop codon at amino acid 2279 of apolipoprotein B-100, producing a severely truncated apoB-50 protein and causing familial hypobetalipoproteinemia type 1 with markedly reduced LDL cholesterol and hepatic steatosis risk

See your personal result for APOB

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

When ApoB Stops Halfway — The Q2279X Truncation and Lifelong Low LDL

Apolipoprotein B-100 (ApoB-100)11 Apolipoprotein B-100 (ApoB-100)
The structural backbone of every LDL and VLDL particle; a 4,536-amino-acid protein that must be assembled in full to form a stable, secretable lipoprotein is the largest secreted protein in the human body. The rs121918388 variant converts codon 2279 of the APOB gene from glutamine (CAG) to a premature stop codon (TAG) on the coding strand — or equivalently, the G>A change seen on the GRCh38 plus strand. The result is a truncated protein approximately 50% the length of full-length ApoB-100, designated apoB-50, that cannot support normal lipoprotein secretion. Heterozygous carriers consistently show LDL cholesterol well below the population norm — a pattern that sharply reduces coronary heart disease risk while introducing a distinct risk of hepatic fat accumulation.

The Mechanism

Full-length ApoB-100 is the non-exchangeable scaffold of LDL and VLDL particles22 LDL and VLDL particles
Low-density and very-low-density lipoproteins — the primary cholesterol-carrying particles in blood; each contains exactly one ApoB-100 molecule assembled in the endoplasmic reticulum of liver hepatocytes. The Q2279X stop codon truncates the protein at roughly the midpoint of its full length, eliminating all C-terminal domains required for stable lipoprotein particle assembly and LDL receptor recognition.

A related intestinal isoform, ApoB-48, spans approximately the first 2,153 amino acids (48% of ApoB-100) and packages dietary fat into chylomicrons for lymphatic absorption. Because the Q2279X truncation occurs at residue 2279 — just downstream of the ApoB-48 editing site — the truncated apoB-50 protein retains the ApoB-48 functional domain intact. In heterozygous carriers, the one intact APOB allele produces full-length ApoB-100 normally, which is sufficient for adequate lipoprotein secretion; LDL cholesterol is reduced but not absent. In the exceedingly rare homozygous state, both alleles produce apoB-50 rather than full-length protein, severely impairing hepatic VLDL secretion and potentially compromising fat-soluble vitamin transport.

The Evidence

Peloso et al. (2019)33 Peloso et al. (2019) sequenced APOB across 57,973 individuals in 12 case-control studies and identified 37 distinct protein-truncating variants. Heterozygous carriers showed 43 mg/dL lower LDL-C, a 30% reduction in triglycerides, and a 72% lower risk for coronary heart disease44 72% lower risk for coronary heart disease
OR 0.28; 95% CI 0.12–0.64; P=0.002. This magnitude of LDL reduction, sustained over a lifetime, is comparable to or exceeding the benefit of high-intensity statin therapy.

The tradeoff is hepatic steatosis. Ferri et al. (2025)55 Ferri et al. (2025) showed that APOB loss-of-function carriers have lower atherosclerotic cardiovascular disease risk but increased chronic liver disease risk — particularly in the presence of diabetes and obesity. Hepatic ultrasound studies find steatosis in up to 73% of carriers in clinical referral cohorts, though the prevalence in unselected population carriers is lower. About 5–10% of heterozygous carriers develop nonalcoholic steatohepatitis (NASH), and progression to cirrhosis is documented but rare.

GeneReviews (Burnett et al., 2021)66 GeneReviews (Burnett et al., 2021) defines the surveillance standard: fasting lipid panel and liver function tests every 1–2 years in heterozygous carriers; hepatic ultrasound every 3 years if transaminases are persistently elevated. Serum fat-soluble vitamin levels (A, D, E, K) are checked only when gastrointestinal symptoms suggest impaired chylomicron formation — a clinical scenario unusual in heterozygotes but essential to recognize.

rs121918388 is exceptionally rare in population databases; the A allele appears at a frequency of approximately 0.00001 globally in the PAGE study (1 carrier in ~78,000 individuals), with no homozygotes identified in any large sequencing effort. This rarity is typical of severely truncating APOB alleles, which are under negative selection in the homozygous state.

Practical Actions

Heterozygous carriers (AG genotype) rarely require any pharmacological intervention. The naturally low LDL is cardioprotective; it is the hepatic fat deposition and the minority risk of NASH that require periodic surveillance. Knowing about this variant is particularly valuable before starting any LDL-lowering medication — the already-reduced baseline changes the dosing calculus and makes standard lipid targets potentially inappropriate.

Interactions

APOB rs121918388 heterozygosity creates a chronic low-LDL state that compounds with PCSK9 loss-of-function variants (rs11591147, rs562556): carriers of both an APOB truncation and a PCSK9 LOF variant may have near-absent LDL-C, making ApoB protein measurement (rather than calculated LDL-C) the preferred lipid biomarker. Within the APOB gene, other truncating variants — including the frameshift rs121918384 (p.Val1856fs) — produce the same FHBL1 phenotype; compound heterozygosity for two different APOB loss-of-function alleles produces biallelic disease equivalent to the homozygous state.

Nutrient Interactions

vitamin E reduced_absorption
vitamin A reduced_absorption
vitamin D reduced_absorption
vitamin K reduced_absorption

Genotype Interpretations

What each possible genotype means for this variant.

GG Non-carrier Normal

No APOB Q2279X variant — standard apolipoprotein B-100 production

You carry two intact copies of the APOB gene at this position and produce full-length apolipoprotein B-100 normally. Your liver assembles LDL and VLDL particles as expected, and your lipid profile is not affected by this variant. The rs121918388 stop allele is exceptionally rare, present in roughly 1 in 78,000 individuals across the populations studied, and is not detected in most large-scale sequencing databases.

AG Heterozygous Carrier Carrier

One truncated APOB copy — markedly lower LDL and reduced cardiovascular risk, with liver monitoring warranted

Familial hypobetalipoproteinemia type 1 (FHBL1) caused by APOB nonsense variants follows a codominant pattern: one truncated allele lowers LDL measurably; two truncated alleles produce severe disease. In the heterozygous state, the clinical picture is dominated by unexpectedly low LDL on routine lipid testing — often as low as 30–60 mg/dL — which can prompt investigation for secondary causes (malnutrition, thyroid disease, liver failure) before the genetic basis is identified. Once confirmed, the finding is reassuring for cardiovascular risk but warrants ongoing hepatic surveillance.

Fat-soluble vitamin absorption is generally unaffected in heterozygotes because the one intact APOB allele supports adequate chylomicron formation. However, if gastrointestinal symptoms develop, fat-soluble vitamin levels should be checked, as partial ApoB impairment can occasionally reduce absorption sufficiently to produce subclinical deficiencies (vitamin E deficiency identified in ~27% of FHBL carriers in one clinical cohort, vitamin D insufficiency in ~67%).

Published surveillance guidelines (GeneReviews 2021) recommend fasting lipid panel and liver function tests every 1–2 years, with hepatic ultrasound every 3 years if transaminases are persistently elevated.

AA Homozygous Homozygous

Both APOB copies truncated — severe lipoprotein impairment requiring specialist management

Biallelic APOB-FHBL caused by nonsense mutations produces a phenotype approaching abetalipoproteinemia in severity. Without sufficient full-length ApoB-100, hepatocytes cannot export VLDL, causing intracellular fat accumulation and steatohepatitis. Without adequate chylomicron assembly in enterocytes, dietary fat and fat-soluble vitamins accumulate in intestinal cells rather than reaching systemic circulation.

The Q2279X truncation at residue 2279 falls just past the ApoB-48 editing site (codon 2153), so the apoB-50 protein retains the ApoB-48 functional region. In theory this means intestinal lipid packaging may be partially preserved compared to shorter truncations (e.g., apoB-37 or apoB-31), which would fall within the ApoB-48 domain. However, the clinical consequences in biallelic disease are still expected to be severe.

Management parallels the biallelic FHBL1 protocol established in GeneReviews (Burnett et al., 2021): high-dose fat-soluble vitamin supplementation initiated early, before irreversible neurological or retinal damage, combined with a low-fat diet to reduce intestinal fat load.